MeKin Duo
Vitamin K2 is an essential dietary principle not only to ensure blood coagulation but it is also an important responsible element in the prevention of bone fragility.
Let's see in more detail what its properties are:
Cardiovascular protection:
Vitamin K2 promotes the enzymatic activation of a protein present in blood vessels (mGLA) that binds calcium by preventing its deposition at the level of the vessel wall. In fact, excessive calcification of the arterial wall is a cardiovascular risk factor since, in addition to increasing its fragility and rigidity, it hinders normal blood flow.
Bone protection:
Osteocalcin is a protein expressed mainly in osteoblasts and involved in bone metabolism. Strictly dependent on vitamin K, osteocalcin is essential for maintaining calcium homeostasis. While vitamin D3 induces osteocalcin synthesis, vitamin K2 is involved in its activation; in fact it acts as a co-factor of the enzyme able to activate osteocalcin through a carboxylation process at specific sites of the protein. In the activated form (carboxylate), osteocalcin is able to bind calcium and favor its deposit at the level of the bone matrix.
Vitamin K2 is fundamental in the prevention of osteoporosis. Scientific studies confirm that it is essential for bone health.
It has been established that vitamin K2 is a much more effective osteocalcin activator than vitamin K1.
The recommended daily allowance (RDA) of vitamin K2 is about 1 mcg / kg, unfortunately it is not easy to reach an "acceptable" dose proportionate to our weight by means of diet alone: if we consider that to reach only 45 mcg, we should take every day for example 8 eggs or at least 5 liters of milk. The only food that is very rich in vitamin K2 is natto (a typical food of the Japanese tradition based on fermented soy beans) which, however, is not part of our culinary tradition.
What is Mekin Duo?
MeKin Duo is a food supplement based on vitamin K2 MK-7, vitamin B2 (Riboflavin) and magnesium, useful in cases of reduced dietary intake or increased nutrient requirements.
Main properties of MeKin Duo components?
Vitamin K2 has a dual action, both at bone and cardiovascular level, as a co-factor of important proteins involved in bone metabolism and blood coagulation.
• Vitamin K2, in the form of menaquinone-7, promotes the absorption of calcium in the bone matrix by activating osteocalcin, preventing the deposit of calcium in the soft tissues and arteries.
• Vitamin B2 (Riboflavin) intervenes in the activation of hydrolase, an enzyme necessary for the action of vitamin D.
• Magnesium helps muscle function and helps maintain healthy bones.
Composition
Vitamin K2 (menaquinone-7)
Vitamin B2 (riboflavin)
Magnesium
Daily dose and method of employment
Swallow 1 capsule a day preferably after the main meal or as advised by your doctor.
Warnings
The supplements are not intended as a substitute for a varied and balanced diet and a healthy lifestyle. Do not exceed the recommended daily dose. Keep out of reach of children under three years of age. Do not take in case of hypersensitivity or allergies to one or more components. If you are taking anticoagulant drugs consult your doctor before taking the product.
Format Pack
Pack of 30 capsules of 500 mg
Preservation rules
Store in a cool, dry place at a temperature not exceeding 25 ° - 30 ° C, away from light and / or heat sources. The minimum storage term refers to the product properly stored in unopened package.
References
1. Greenland, P., et al., ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular
risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus
Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration
with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol, 2007.
49(3): p. 378-402.
2. Karwowski, W., et al., The mechanism of vascular calcification - a systematic review. Med Sci Monit, 2012. 18(1): p. RA1-11.
3. Bild, D.E., et al., Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation, 2005. 111(10): p. 1313-20.
4. Iribarren, C., et al., Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA,
2000. 283(21): p. 2810-5.
5. Rosenhek, R., et al., Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med, 2000. 343(9): p. 611-7.
6. Dalmeijer, G.W., et al., Matrix Gla protein species and risk of cardiovascular events in type 2 diabetic patients. Diabetes Care, 2013. 36(11): p. 3766-71.
7. Cranenburg, E.C., et al., Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost, 2010. 104(4): p.
811-22.
8. Ueland, T., et al., Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med,
2010. 268(5): p. 483-92.
9. Keutel, J., G. Jorgensen, and P. Gabriel, [A new autosomal-recessive hereditary syndrome. Multiple peripheral pulmonary stenosis, brachytelephalangia,
inner-ear deafness, ossification or calcification of cartilages]. Dtsch Med Wochenschr, 1971. 96(43): p. 1676-81 passim.
10. van den Heuvel, E.G., et al., Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. Maturitas,
2014. 77(2): p. 137-41.
11. Cranenburg, E.C., L.J. Schurgers, and C. Vermeer, Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost, 2007. 98(1): p. 120-5.
12. Schurgers, L.J., et al., Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood, 2007. 109(8):
p. 3279-83.
13. Theuwissen, E., et al., Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in
healthy subjects. Br J Nutr, 2012. 108(9): p. 1652-7.
14. Theuwissen, E., et al., Vitamin K status in healthy volunteers. Food Funct, 2014. 5(2): p. 229-34.
15. Ansell, J., et al., The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic
Therapy. Chest, 2004. 126(3 Suppl): p. 204S-233S.
16. Caraballo, P.J., et al., Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med, 1999. 159(15): p. 1750-6.
17. Lerner, R.G., et al., Warfarin use and the risk of valvular calcification. J Thromb Haemost, 2009. 7(12): p. 2023-7.
18. Weijs, B., et al., Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients.
Eur Heart J, 2011. 32(20): p. 2555-62.
19. Danziger, J., et al., Vitamin K-Dependent Protein Activity and Incident Ischemic Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis. Arterioscler
Thromb Vasc Biol, 2016. 36(5): p. 1037-42.
20. Vermeer, C., Vitamin K: the effect on health beyond coagulation - an overview. Food Nutr Res, 2012. 56.
21. Shea, M.K., et al., Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults.
J Nutr, 2011. 141(8): p. 1529-34.
22. Westenfeld, R., et al., Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis,
2012. 59(2): p. 186-95.
23. WHO Cardiovascular Disease (CVDs), Factsheet No. 317, (2016).
24. Townsend, N., et al., Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J, 2016. 37(42): p. 3232-3245.
25. Ovbiagele, B., et al., Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke
Association. Stroke, 2013. 44(8): p. 2361-75.
26. Booth, S.L., Roles for vitamin K beyond coagulation. Annu Rev Nutr, 2009. 29: p. 89-110.
27. Fujita, Y., et al., Association between vitamin K intake from fermented soybeans, natto, and bone mineral density in elderly Japanese men: the Fujiwara-kyo
Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int, 2012. 23(2): p. 705-14.
28. Hamerman, D., Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM, 2005. 98(7): p. 467-84.
29. Kidd, P.M., Vitamins D and K as pleiotropic nutrients: clinical importance to the skeletal and cardiovascular systems and preliminary evidence for synergy.
Altern Med Rev, 2010. 15(3): p. 199-222.
30. Szulc, P., et al., Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study. J Bone Miner Res, 2009. 24(12):
p. 2023-31.
31. den Uyl, D., et al., (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between
cardiovascular disease and osteoporosis. Arthritis Res Ther, 2011. 13(1): p. R5.
32. Hofbauer, L.C., et al., Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. Osteoporos Int, 2007. 18(3): p. 251-9.
33. Jorgensen, L., et al., Carotid plaque echogenicity and risk of nonvertebral fractures in women: a longitudinal population-based study. Calcif Tissue Int, 2006.
79(4): p. 207-13.
34. Lampropoulos, C.E., I. Papaioannou, and D.P. D‘Cruz, Osteoporosis--a risk factor for cardiovascular disease? Nat Rev Rheumatol, 2012. 8(10): p. 587-98.
35. Wiklund, P., et al., Low bone mineral density is associated with increased risk for myocardial infarction in men and women. Osteoporos Int, 2012. 23(3): p. 963-70.
36. Doherty, T.M., et al., Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev, 2004. 25(4): p. 629-72.
37. Duer, M.J., et al., Mineral surface in calcified plaque is like that of bone: further evidence for regulated mineralization. Arterioscler Thromb Vasc Biol, 2008.
28(11): p. 2030-4.
38. Knapen, M.H., et al., Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
Thromb Haemost, 2015. 113(5): p. 1135-44.
39. Moller, M., et al., Bioavailability and Chemical/Functional Aspects of Synthetic MK-7 vs Fermentation-Derived MK-7 in Randomised Controlled Trials. Int J
Vitam Nutr Res, 2016: p. 1-15.
40. Geleijnse, J.M., et al., Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr, 2004. 134(11):
p. 3100-5.
